UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

TigarB causes mitochondrial dysfunction and neuronal loss in PINK1 deficiency

Annals of neurology, 2013-12, Vol.74 (6), p.837-847

2013

Volltextzugriff (PDF)

Zebrafish as a new animal model for movement disorders

Journal of neurochemistry, 2008-09, Vol.106 (5), p.1991-1997

2008

Volltextzugriff (PDF)

Maternal microchimerism in healthy adults in lymphocytes, monocyte/macrophages and NK cells

Laboratory investigation, 2006-11, Vol.86 (11), p.1185-1192

2006

Volltextzugriff (PDF)

Complex I deficiency and dopaminergic neuronal cell loss in parkin-deficient zebrafish (Danio rerio)

Brain (London, England : 1878), 2009-06, Vol.132 (6), p.1613-1623

2009

Volltextzugriff (PDF)

Implementation of an Updated Screening Tool to Identify Human Trafficking Victims in the Emergency Department

Flinn, Laura E

2022

Volltextzugriff (PDF)

TIGAR Inhibition Rescues Dopaminergic Neurons in Common Forms of Early Onset Parkinson's' Disease (I5-2.003)

Neurology, 2014-04, Vol.82 (10_supplement)

2014

Volltextzugriff (PDF)

TIGAR Inhibition Rescues Dopaminergic Neurons in Common Forms of Early Onset Parkinson's' Disease (S7.002)

Neurology, 2014-04, Vol.82 (10_supplement)

2014

Volltextzugriff (PDF)

Genomic analysis of a human interferon -inducible gene family and systemic lupus erythematosus

Flinn, Laura Jeanne

2006

Volltextzugriff (PDF)

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma

Journal of clinical oncology, 2019-05, Vol.37 (14), p.1188-1199

2019

Volltextzugriff (PDF)

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

The New England journal of medicine, 2022-02, Vol.386 (7), p.640-654

2022

Volltextzugriff (PDF)

ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic Leukemia

The New England journal of medicine, 2004-08, Vol.351 (9), p.893-901

2004

Volltextzugriff (PDF)

iDISCO Tissue Clearing Whole-Brain and Light Sheet Microscopy for High-Throughput Imaging in a Mouse Model of Traumatic Brain Injury

Methods in molecular biology (Clifton, N.J.), 2024, Vol.2761, p.589

2024

Volltextzugriff (PDF)

Elemental mapping and quantitative analysis of Cu, Zn, and Fe in rat brain sections by laser ablation ICP-MS

Analytical and bioanalytical chemistry, 2006-02, Vol.384 (4), p.951-957

2006

Volltextzugriff (PDF)

Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia

Proceedings of the National Academy of Sciences - PNAS, 2015-04, Vol.112 (14), p.4322-4327

2015

Volltextzugriff (PDF)

The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia

Oncotarget, 2017-04, Vol.8 (16), p.25942-25954

2017

Volltextzugriff (PDF)

Analysis of peripheral neuropathy (PN) using clinician- and patient-reported outcomes (ClinRO and PRO) in the POLARIX study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.7561-7561

2022

Volltextzugriff (PDF)

The impact of early versus late tocilizumab administration in patients with cytokine release syndrome secondary to immune effector cell therapy

Journal of oncology pharmacy practice, 2023-01, Vol.29 (1), p.45-51

2023

Volltextzugriff (PDF)

Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma

Blood, 2019-11, Vol.134 (Supplement_1), p.1285-1285

2019

Volltextzugriff (PDF)

Efficacy and time to next treatment following lenalidomide/rituximab (R 2 ) or rituximab/placebo in patients with R/R indolent NHL (AUGMENT)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.7514-7514

2019

Volltextzugriff (PDF)

Rituximab With or Without Bevacizumab for the Treatment of Patients With Relapsed Follicular Lymphoma

Clinical lymphoma, myeloma and leukemia, 2014-08, Vol.14 (4), p.277-283

2014

Volltextzugriff (PDF)

AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Blood, 2018-11, Vol.132 (Supplement 1), p.445-445

2018

Volltextzugriff (PDF)

1 – 25 von 44

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(42)
Dissertationen
(2)

Sprache

Englisch
(44)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Science & Technology
(15)
Life Sciences & Biomedicine
(14)
Humans
(10)
Oncology
(7)
Aged
(6)
Aged, 80 And Over
(6)
Female
(6)
Male
(6)
Middle Aged
(6)
Adult
(5)
Animals
(5)
Leukemia
(5)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(4)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(4)
Biological And Medical Sciences
(4)
Chronic Lymphocytic Leukemia
(4)
Medical Sciences
(4)
Danio Rerio
(3)
Disease Models, Animal
(3)
Freshwater
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

TigarB causes mitochondrial dysfunction and neuronal loss in PINK1 deficiency

Zebrafish as a new animal model for movement disorders

Maternal microchimerism in healthy adults in lymphocytes, monocyte/macrophages and NK cells

Complex I deficiency and dopaminergic neuronal cell loss in parkin-deficient zebrafish (Danio rerio)

Implementation of an Updated Screening Tool to Identify Human Trafficking Victims in the Emergency Department

TIGAR Inhibition Rescues Dopaminergic Neurons in Common Forms of Early Onset Parkinson's' Disease (I5-2.003)

TIGAR Inhibition Rescues Dopaminergic Neurons in Common Forms of Early Onset Parkinson's' Disease (S7.002)

Genomic analysis of a human interferon -inducible gene family and systemic lupus erythematosus

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma

Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial

ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic Leukemia

iDISCO Tissue Clearing Whole-Brain and Light Sheet Microscopy for High-Throughput Imaging in a Mouse Model of Traumatic Brain Injury

Elemental mapping and quantitative analysis of Cu, Zn, and Fe in rat brain sections by laser ablation ICP-MS

Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia

Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN

Analysis of peripheral neuropathy (PN) using clinician- and patient-reported outcomes (ClinRO and PRO) in the POLARIX study

The impact of early versus late tocilizumab administration in patients with cytokine release syndrome secondary to immune effector cell therapy

Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma

Efficacy and time to next treatment following lenalidomide/rituximab (R 2 ) or rituximab/placebo in patients with R/R indolent NHL (AUGMENT)

Rituximab With or Without Bevacizumab for the Treatment of Patients With Relapsed Follicular Lymphoma

AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Suchergebnisse filtern